Literature DB >> 3030863

Evaluation of a combined measles-mumps-rubella-chickenpox vaccine.

M Just, R Berger, V Just.   

Abstract

There was neither a difference in the (low) percentage of only harmless side-reactions nor in the rate of sero-conversions (between 95-100%), when groups of 15 to 24 months old children were vaccinated either with the single components or with a combined MMR + Chickenpox-vaccine of a high potency.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3030863

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  7 in total

Review 1.  Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults.

Authors:  Kristine Macartney; Anita Heywood; Peter McIntyre
Journal:  Cochrane Database Syst Rev       Date:  2014-06-23

Review 2.  Vaccines for measles, mumps and rubella in children.

Authors:  Vittorio Demicheli; Alessandro Rivetti; Maria Grazia Debalini; Carlo Di Pietrantonj
Journal:  Cochrane Database Syst Rev       Date:  2012-02-15

Review 3.  Vaccines for measles, mumps, rubella, and varicella in children.

Authors:  Carlo Di Pietrantonj; Alessandro Rivetti; Pasquale Marchione; Maria Grazia Debalini; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2021-11-22

4.  Epidemiology of chickenpox in England and Wales, 1967-85.

Authors:  C A Joseph; N D Noah
Journal:  Br Med J (Clin Res Ed)       Date:  1988-03-05

5.  Vaccines for measles, mumps, rubella, and varicella in children.

Authors:  Carlo Di Pietrantonj; Alessandro Rivetti; Pasquale Marchione; Maria Grazia Debalini; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2020-04-20

Review 6.  Dengue conundrums.

Authors:  Robert V Gibbons
Journal:  Int J Antimicrob Agents       Date:  2010-08-08       Impact factor: 5.283

7.  Varicella in Poland: economic burden in children 1-12 years of age in Poland, 2010-2015.

Authors:  Jacek Wysocki; Ilona Malecka; Joanna Stryczynska-Kazubska; Emmanouil Rampakakis; Barbara Kuter; Lara J Wolfson
Journal:  BMC Public Health       Date:  2018-03-27       Impact factor: 3.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.